和黃醫藥(00013.HK)在中國啓動HMPL-453 Ib/II期臨牀試驗
和黃醫藥(00013.HK)公佈,在中國啓動了一項HMPL-453的Ib/II期臨牀試驗,評估HMPL-453與化療或特瑞普利單抗的聯合療法。HMPL-453是一種新型且選擇性的研究性靶向成纖維細胞生長因子受體1/2/3的抑制劑。首名患者已於2022年1月22日接受給藥治療。
該試驗是一項多中心、兩階段、開放標籤的研究,旨在評估HMPL-453聯合療法治療特定的晚期或轉移性實體瘤患者的安全性、耐受性、藥代動力學和初步療效特徵。
研究的第一階段爲劑量探索階段,第二階段爲劑量擴展階段。各實體瘤隊列將分別接受特定的HMPL-453和化療或抗PD-1聯合療法,以進一步評估使用RP2D治療的初步療效、安全性及耐受性等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.